These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 27156108)

  • 21. Hemolytic anemias during pregnancy and the reproductive years.
    Mintz U; Moohr JW; Ultmann JE
    J Reprod Med; 1977 Nov; 19(5):243-53. PubMed ID: 562940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease.
    Berentsen S
    Semin Hematol; 2018 Jul; 55(3):141-149. PubMed ID: 30032751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of cryptantigen Th on paroxysmal nocturnal hemoglobinuria erythrocytes in association with a hemolytic exacerbation.
    Nakakuma H; Hidaka M; Nagakura S; Nishimura Y; Iwamoto N; Horikawa K; Kawaguchi T; Kagimoto T; Takatsuki K
    J Clin Invest; 1995 Jul; 96(1):201-6. PubMed ID: 7542278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Examining coagulation-complement crosstalk: complement activation and thrombosis.
    Foley JH
    Thromb Res; 2016 May; 141 Suppl 2():S50-4. PubMed ID: 27207425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cold agglutinin-mediated autoimmune hemolytic anemia.
    Berentsen S; Randen U; Tjønnfjord GE
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):455-71. PubMed ID: 26043385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
    Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
    Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hemolytic anemia, myocardial infarction and xenotransplantation: what do they have in common?].
    Schifferli JA
    Schweiz Med Wochenschr; 1995 Nov; 125(46):2217-25. PubMed ID: 8525341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of pregnancy and delivery in patients with paroxysmal nocturnal hemoglobinuria].
    Usuki K
    Rinsho Ketsueki; 2015 Jul; 56(7):785-94. PubMed ID: 26251141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of complement inhibition in PNH.
    Hillmen P
    Hematology Am Soc Hematol Educ Program; 2008; ():116-23. PubMed ID: 19074068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Coagulation and complement crosstalk: molecular mechanisms of complement-mediated diseases].
    Tsujimoto H; Inoue N
    Rinsho Ketsueki; 2024; 65(6):576-583. PubMed ID: 38960659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pregnancy-induced hemolytic anemia with a possible immune-related mechanism.
    Katsuragi S; Sameshima H; Omine M; Ikenoue T
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):528-9. PubMed ID: 18239010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH).
    Shichishima T
    Fukushima J Med Sci; 1995 Jun; 41(1):1-13. PubMed ID: 8606038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement inhibitors to treat IgM-mediated autoimmune hemolysis.
    Wouters D; Zeerleder S
    Haematologica; 2015 Nov; 100(11):1388-95. PubMed ID: 26521297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hemolytic disorders and venous thrombosis: An update].
    Lecouffe-Desprets M; Graveleau J; Artifoni M; Connault J; Agard C; Pottier P; Hamidou M; Néel A
    Rev Med Interne; 2019 Apr; 40(4):232-237. PubMed ID: 30773236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria.
    Bessler M; Hiken J
    Hematology Am Soc Hematol Educ Program; 2008; ():104-10. PubMed ID: 19074066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway.
    Vaught AJ; Braunstein E; Chaturvedi S; Blakemore K; Brodsky RA
    J Matern Fetal Neonatal Med; 2022 Apr; 35(7):1392-1400. PubMed ID: 32338085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016.
    Hansen DL; Möller S; Andersen K; Gaist D; Frederiksen H
    Clin Epidemiol; 2020; 12():497-508. PubMed ID: 32547241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombosis, Microangiopathies, and Inflammation.
    Matevosyan K; Sarode R
    Semin Thromb Hemost; 2015 Sep; 41(6):556-62. PubMed ID: 26276936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune hemolysis-serological and clinical aspects.
    Pruss A; Salama A; Ahrens N; Hansen A; Kiesewetter H; Koscielny J; Dörner T
    Clin Exp Med; 2003 Sep; 3(2):55-64. PubMed ID: 14598182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.